Effects of adiponectin, plasma D-dimer, inflammation and tumor markers on clinical characteristics and prognosis of patients with ovarian cancer

Li, Hui; Sun, Lulu; Chen, Lili; Kang, Zhihui; Hao, Guorong; Feng-lou, Bai

doi:10.5937/jomb0-26452

Cited by 9 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Obese PCOS patients with hormonal imbalances. AMH is secreted by granulosa cells with a diameter of less than 8 mm, and AMH levels can be used to estimate the number of early sinus follicles in the ovary [11] . There is evidence to suggest that obese PCOS women display an approximately twofold increase in AMH levels compared to non-PCOS patients.…”

Section: Discussionmentioning

confidence: 99%

Clinical observation of laparoscopic sleeve gastrectomy and metformin treatment in obese PCOS patients

Ma,

He,

et al. 2024

J Med Biochemistry

View full text Add to dashboard Cite

Background: to observe the basic metabolic characteristics of obese patients with PCOS, and observe and compare the effect of laparoscopic sleeve gastrectomy and metformin treatment after 3 months. Methods: In January to December 2018, the Second Hospital of Hebei Medical University selected 104 women who were classified as obese with a BMI of 28kg/cm2 or higher and had PCOS. They were divided into obese PCOS group (53 cases) and obese non-pcos group (51 cases). Results: 1. There was no significant difference in waist circumference and WHR between patients who are obese with PCOS and patients who are obese without PCOS (P > 0.05).Obese PCOS patients were significantly higher in AMH, LH/FSH, T, FAI, homa-ir, TG, LDL, apo-b and uric acid than the group of non-PCOS patients who were obese. (P<0.05). The SHBG levels of obese patients with PCOS were obviously lower when contrasted with the levels in obese patients without PCOS (P < 0.05). 2. Body weight, BMI, INS, homa-ir and TG of obese PCOS patients were significantly decreased 3 months after laparoscopic sleeve gastrectomy compared with that before surgery (P < 0.05). After three months of medical treatment with metformin, the patients' HOMA-IR was obviously reduced when contrasted with the pre-treatment HOMA-IR levels (P < 0.05), and there was no significant difference in the improvement degree of homa-ir between the two groups (P > 0.05). Conclusion: 1. Obese patients with PCOS demonstrated higher expression of AMH, LH/FSH, T, SHBG, and FAI when contrasted with the control group. Additionally, they experienced more severe insulin resistance and lipid metabolism disorders. 2. The weight and BMI of obese PCOS patients were significantly decreased after weight loss, while IR and blood lipid were significantly improved, while IR was improved in metformin group, and no significant discrepancy was observed in the degree of improvement of insulin resistance between both groups.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical observation of laparoscopic sleeve gastrectomy and metformin treatment in obese PCOS patients

Ma,

He,

et al. 2024

J Med Biochemistry

View full text Add to dashboard Cite

show abstract

“…Decreased serum adiponectin and expression of adiponectin receptors AdipoR1 and AdipoR2 are associated with poor outcomes in ovarian cancer 157–159 . However, limited studies have investigated the underlying mechanisms related to these findings.…”

Section: Methodsmentioning

confidence: 99%

“…Decreased serum adiponectin and expression of adiponectin receptors AdipoR1 and AdipoR2 are associated with poor outcomes in ovarian cancer. 157 , 158 , 159 However, limited studies have investigated the underlying mechanisms related to these findings. The protective role of adiponectin in ovarian cancer was studied via AdipoRon, a small molecule agonist of the adiponectin receptor.…”

Section: Methodsmentioning

confidence: 99%

The impact of obesity and adipokines on breast and gynecologic malignancies

Tewari

Vargas

Reizes

2022

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

The link between obesity and multiple disease comorbidities is well established. In 2003, Calle and colleagues presented the relationship between obesity and several cancer types, including breast, ovarian, and endometrial malignancies. Nearly, 20% of cancer‐related deaths in females can be accounted for by obesity. Identifying obesity as a risk factor for cancer led to a focus on the role of fat‐secreted cytokines, known as adipokines, on carcinogenesis and tumor progression. Early studies indicated that the adipokine leptin increases cell proliferation, invasion, and inhibition of apoptosis in multiple cancer types. As a greater appreciation of the obesity–cancer link has amassed, we now know that additional adipokines can impact tumorigenesis. A deeper understanding of the adipokine‐activated signaling in cancer may identify new treatment strategies irrespective of obesity. Moreover, adipokines may serve as disease biomarkers, harnessing the potential of obesity‐associated factors to serve as indicators of treatment response and disease prognosis. As studies investigating obesity and women's cancers continue to expand, it has become evident that breast, ovarian, and uterine cancers are distinctly impacted by adipokines. While complex, these distinct interactions may provide insight into cancer progression in these organs and new opportunities for targeted therapies. This review aims to organize and present the literature from the last 5 years investigating the mechanisms and implications of adipokine signaling in breast, endometrial, and ovarian cancers with a special focus on leptin and adiponectin.

show abstract

“…The relationship between obesity and ovarian tumor development has become increasingly evident, particularly in post-menopausal women ( 25 ). In case-control studies, women with low levels of adiponectin have higher risk for ovarian cancer ( 26 , 27 ). Adiponectin receptors are expressed in both epithelial and granulose ovarian cancer cells ( 28 ) and their expression is associated with more advanced cancer and shorter progression-free and overall survival ( 29 ).…”

Section: Adiponectin and Ovarian Cancermentioning

confidence: 99%

Adiponectin: A player in the pathogenesis of hormone-dependent cancers

Tsankof

Τζιόμαλος²

2022

Front. Endocrinol.

View full text Add to dashboard Cite

Hormone-dependent cancers are a major cause of morbidity and mortality in both genders. Accumulating evidence suggest that adiponectin, an adipokine with multifaceted functions, is implicated in the pathogenesis of several malignancies. In the present review, we discuss the existing data regarding this relationship. Several observational studies showed that low adiponectin levels are associated with higher risk for breast, cervical, endometrial, ovarian and prostate cancer. A relationship between adiponectin and the aggressiveness of some of these tumors has also been reported. In vitro studies reported that adiponectin inhibits the proliferation and induces apoptosis of breast, cervical, endometrial, ovarian and prostate cancer cells. Given the high prevalence of these cancers and the substantial associated morbidity and mortality, the role of agents that increase adiponectin levels and/or stimulate its activity should be evaluated for the prevention and management of these common tumors.

show abstract

Effects of adiponectin, plasma D-dimer, inflammation and tumor markers on clinical characteristics and prognosis of patients with ovarian cancer

Cited by 9 publications

References 19 publications

Clinical observation of laparoscopic sleeve gastrectomy and metformin treatment in obese PCOS patients

Clinical observation of laparoscopic sleeve gastrectomy and metformin treatment in obese PCOS patients

The impact of obesity and adipokines on breast and gynecologic malignancies

Adiponectin: A player in the pathogenesis of hormone-dependent cancers

Contact Info

Product

Resources

About